SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Intermediate follow-up) — Richard Roundtree

PatientRichard Roundtree
Date of birth1975-07-09
IdentifiersMRN HR-ML015-SYN; SSN (made up) 000-15-8410
Document date2026-10-05
AuthorLeon Carrington, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Biopsy results for a left breast lump. [S]

History of Present Illness

Mr. Roundtree returns six days after first coming in with a painless lump under the left nipple. Diagnostic mammography and ultrasound of both breasts and both axillae the next day showed a 1.6 cm irregular mass eccentric to the left nipple and one abnormal left axillary lymph node; the right breast and axilla were normal. Core biopsies of the mass and the node the same day show invasive ductal carcinoma, grade 3, estrogen receptor 95 percent, progesterone receptor 85 percent, HER2 negative, with cancer in the node. He was asked to come in so the result could be given in person. He says he had not thought a man could get breast cancer and had been sure it was the breast enlargement he had at 13. He has no bone pain, cough, headache, abdominal pain, or weight loss. He saw Dr. Siddiqui of breast surgical oncology this morning, and the operation is booked in two days. His main worries are the operation, whether he can keep working, and keeping the diagnosis private. [S]

ElementDetail
DiagnosisInvasive ductal carcinoma, left breast, grade 3, ER and PR positive, HER2 negative; left axillary node positive
Other breast and axillaNormal on mammography and ultrasound
Symptoms of spreadNone
CoordinationSurgical oncology seen today; operation in two days
ConcernsThe operation, work, and privacy

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo weight loss, fever, or night sweats
RespiratoryNegativeNo cough or breathlessness
MusculoskeletalNegativeNo bone pain
NeurologicalNegativeNo headache or weakness
GastrointestinalNegativeNo abdominal pain
PsychiatricPositiveWorried and shaken; sleeping less; PHQ-9 score 5; no thoughts of self-harm

6 systems reviewed. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-05Body height188cmS
2026-10-05Body weight85.6kgS
2026-10-05Body mass index (BMI) [Ratio]24.2kg/m2S
2026-10-05Systolic blood pressure134mm[Hg]S
2026-10-05Diastolic blood pressure82mm[Hg]S
2026-10-05Heart rate82/minS
2026-10-05Respiratory rate16/minS
2026-10-05Body temperature36.8CelS
2026-10-05Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-05Hemoglobin [Mass/volume] in Blood14.8g/dL13.2-16.6 g/dLNormalS
2026-10-05Leukocytes [#/volume] in Blood by Automated count6.610*3/uL4-11 10*3/uLNormalS
2026-10-05Neutrophils [#/volume] in Blood by Automated count3.910*3/uL1.5-7.7 10*3/uLNormalS
2026-10-05Platelets [#/volume] in Blood by Automated count24610*3/uL150-400 10*3/uLNormalS
2026-10-05Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-10-05Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
2026-10-05Creatinine [Mass/volume] in Serum or Plasma1.02mg/dL0.74-1.35 mg/dLNormalS
2026-10-05Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M89mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-05Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
2026-10-05Calcium [Mass/volume] in Serum or Plasma9.5mg/dL8.6-10.3 mg/dLNormalS
2026-10-05Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-55 U/LNormalS
2026-10-05Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-48 U/LNormalS
2026-10-05Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma71U/L40-129 U/LNormalS
2026-10-05Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
2026-10-05Albumin [Mass/volume] in Serum or Plasma4.4g/dL3.5-5 g/dLNormalS
2026-10-05Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S

Physical Exam

Vital signs recorded on 2026-10-05; see the Vital Signs section. [S]

SystemFinding
GeneralWell; anxious but composed
BreastsLeft: 1.5 cm firm, irregular, painless mass eccentric to the nipple at 2 o'clock, not fixed to the chest wall; mild bruising from the biopsy; no nipple retraction or discharge. Right: no mass and no glandular enlargement
Lymph nodesOne firm, mobile 1 cm left axillary node; no right axillary, supraclavicular, or cervical nodes
AbdomenSoft; liver not enlarged
MusculoskeletalNo spinal tenderness

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the left male breast, central (retroareolar) portion, presenting as a 1.5 cm firm, painless lump eccentric to the left nipple with a palpable left axillary node; core biopsy: grade 3, ER positive, PR positive, HER2 negative, with metastatic carcinoma in the node; clinical stage IIA (cT1c cN1 M0); synthetic modern detail linked to his publicly disclosed breast canceractiveconfirmed C50.122S — Synthetic size, grade, receptor status, and stage; the left-sided lump, the operation, and the spread to lymph nodes are from his public account (D).
Estrogen receptor-positive status of the breast canceractiveconfirmed Z17.0S — Synthetic receptor result; his tumor biology was not made public.
New firm, painless lump of about 1.5 cm just off the left nipple, with a palpable left axillary node; suspected breast cancer, imaging and core biopsy bookedresolvedconfirmed N63.42S — Synthetic presenting concern at the index visit, superseded by the biopsy diagnosis; the left-sided lump is from his public account (D).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingDiagnostic mammography and ultrasound of both breasts and both axillaeAt diagnosisUp to dateDone the day after the first visit: left mass BI-RADS 5 with one abnormal node; right breast and axilla normal
LaboratoryCore biopsy with ER, PR, and HER2 statusAt diagnosisUp to dateInvasive ductal carcinoma, grade 3, ER 95 percent, PR 85 percent, HER2 1+ (negative), Ki-67 30 percent; node positive
LaboratoryPreoperative blood count and chemistryBefore surgeryCompleted todayAll normal: hemoglobin 14.8 g/dL, platelets 246, creatinine 1.02 mg/dL, eGFR 89, calcium 9.5 mg/dL, ALT 24 and alkaline phosphatase 71 U/L
ImagingStaging CT, bone scan, or PETOnly for clinical stage III or symptoms or abnormal results suggesting spreadNot indicatedClinical stage IIA with no symptoms and normal calcium, alkaline phosphatase, and liver tests
LaboratoryGermline multigene panel testingOnce, for every man with breast cancerOrderedSent today; the result is not needed before surgery
ReferralBreast surgical oncologyAt diagnosisCompleted todaySeen this morning; recommendations in the consultation note
ExaminationBaseline arm circumference before axillary surgeryOnce, before axillary surgeryDeferredNot measured today, a deviation from the protocol; the visit was taken up with the diagnosis and the plan. To be addressed after surgery
SurveyDistress and depression screen (PHQ-9)At diagnosis and each visitCompleted todayPHQ-9 score 5, mild, with worry about the operation and work; no thoughts of self-harm
Self-managementInformation and supportAt diagnosisCompleted todayTold plainly that men get breast cancer and that it is treated as well in men as in women; written information for men with breast cancer and details of a peer-support group given; confidential handling of his records and a work note offered

Goal progress:

Guideline basis: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024;42(5):584-604 (2024); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)

Follow-up: Surgery in two days. Primary care review about two weeks after surgery, after the pathology. Medical oncology after the pathology. Call the surgical team for fever, wound redness, or a swelling under the arm. Next scheduled visit 2026-10-20: review two weeks after mastectomy and axillary dissection: pathology, wound and arm care, and preparation for chemotherapy. [S]